(Q37179956)

English

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

scientific article published on 31 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial (English)

1 reference

Europe PubMed Central

18 August 2017

phase II clinical trial

0 references

0 references

Alzheimer's disease

0 references

5

object named as

Kaj Blennow

1 reference

Europe PubMed Central

18 August 2017

Frederik Barkhof

4

object named as

Frederik Barkhof

1 reference

Europe PubMed Central

18 August 2017

Peter Bartenstein

3

object named as

Peter Bartenstein

1 reference

Europe PubMed Central

18 August 2017

2

object named as

Axel Rominger

1 reference

Europe PubMed Central

18 August 2017

object named as

Julius Popp

9

1 reference

ORCID Public Data File 2021

Katharina Buerger

12

object named as

Katharina Buerger

1 reference

Europe PubMed Central

18 August 2017

Yaroslav Winter

7

object named as

Yaroslav Winter

1 reference

Europe PubMed Central

18 August 2017

23

object named as

Frank Jessen

1 reference

Europe PubMed Central

18 August 2017

1

object named as

Richard Dodel

1 reference

Europe PubMed Central

18 August 2017

Martin R. Farlow

22

object named as

Martin Farlow

1 reference

Europe PubMed Central

18 August 2017

author name string

Stefan Förster

6

1 reference

Europe PubMed Central

18 August 2017

Jan-Philipp Bach

8

1 reference

Europe PubMed Central

18 August 2017

Judith Alferink

10

1 reference

Europe PubMed Central

18 August 2017

Jens Wiltfang

11

1 reference

Europe PubMed Central

18 August 2017

Markus Otto

13

1 reference

Europe PubMed Central

18 August 2017

Piero Antuono

14

1 reference

Europe PubMed Central

18 August 2017

Michael Jacoby

15

1 reference

Europe PubMed Central

18 August 2017

Ralph Richter

16

1 reference

Europe PubMed Central

18 August 2017

James Stevens

17

1 reference

Europe PubMed Central

18 August 2017

Isaac Melamed

18

1 reference

Europe PubMed Central

18 August 2017

Jerome Goldstein

19

1 reference

Europe PubMed Central

18 August 2017

Stefan Haag

20

1 reference

Europe PubMed Central

18 August 2017

Stefan Wietek

21

1 reference

Europe PubMed Central

18 August 2017

publication date

31 January 2013

1 reference

Europe PubMed Central

18 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

18 August 2017

12

1 reference

Europe PubMed Central

18 August 2017

3

1 reference

Europe PubMed Central

18 August 2017

233-243

1 reference

Europe PubMed Central

18 August 2017

Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Alzheimer's disease: clinical trials and drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Current state of immunotherapy for Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

“Mini-mental state”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

6 September 2017

Microbleeds do not affect rate of cognitive decline in Alzheimer disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

3 September 2018

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

3 September 2018

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

3 September 2018

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4986921

3 September 2018

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/23375965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and validation of a geriatric depression screening scale: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970014-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970014-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970014-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970014-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse effects of treatment with intravenous immunoglobulins for neurological diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970014-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970014-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970014-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(13)70014-0

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37179956&oldid=1935941124"